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Porphyrias are metabolic diseases that affect about 1 in
20,000 of the EU population. Most healthcare profes-
sionals rarely encounter these disorders and there is dis-
parity between countries in the levels of support
provided for patients and their carers.
EPNET is a DG Sanco funded project (1/4/2007-31/3/
2010) with 15 participating countries that aims to estab-
lish a network of specialist porphyria centres, each
working to agreed quality criteria. Work achieved:
1. Information on porphyria for patients in 10 lan-
guages, and for healthcare professionals in English, is
available at http://www.porphyria-europe.org with easily
downloadable pdf files.
2. Data on the safety of drugs in acute porphyria has
been collected from participating countries (2901 drug
reports on 616 drugs). Information is disseminated on
http://www.drugs-porphyria.org
3. European Quality Assessment (EQA) schemes have
been established for specialist laboratories (24 partici-
pants in 17 countries) and data on laboratory perfor-
mance collected annually. Variations between centres
are being addressed and diagnostic protocols developed.
4. The EPNET registry now contains data on 371
patients (320 new cases; 51 with long term complica-
tions) that is being used to calculate the incidence of
each porphyria in participating countries and the preva-
lence of long term complications, The incidence of new
cases of acute intermittent porphyria is around 0.15/mil-
lion/year in most countries.
The initial purposes of the EPNET project have been
achieved; we have established a rich data resource, a
network for improving quality of care and a European
platform for expert exchange.
EPNET has been funded by the European Commission
through its Public Health and Consumer Protection
Directorate (DG SANCO), PHEA programme.
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